Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4663 - CA209-9DX: Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab vs Placebo for Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence after Curative Resection or Ablation


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Immunotherapy;  Surgical Oncology

Tumour Site

Hepatobiliary Cancers


Maria Jimenez Exposito


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


M.J. Jimenez Exposito1, M. Akce2, J.L. Montero Alvarez3, E. Assenat4, L.A. Balart5, A.D. Baron6, T. Decaens7, A. Heurgue-Berlot8, A.O. Martin9, S.W. Paik10, V. Poulart11, A.S. Sehbai12, N. Takemura13, J. Yoon14

Author affiliations

  • 1 Clinical Development – Oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 2 Department Of Hematology And Medical Oncology, Winship Cancer Institute of Emory University, 30322 - Atlanta/US
  • 3 Gastroenterology, Hospital Universitario Reina Sofia, 14004 - Cordoba/ES
  • 4 Medical Oncology, CHU de Montpellier - Hospital Saint Eloi, 34295 - Montpellie/FR
  • 5 Internal Medicine, Tulane Medical Center, Tulane University health Sciences Center, 70112 - New Orleans/US
  • 6 Medical Center, California Pacific, San Francisco/US
  • 7 Clinique Universitaire D’hépato-gastroentérologie, CHU Grenoble Alpes, Grenoble/FR
  • 8 Department Of Hepato-gastroenterology, Centre Hospitalier Universitaire Reims, Reims/FR
  • 9 Digestive System Service, Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz, 28046 - Madrid/ES
  • 10 Gastroenterology, Samsung Medical Center, Sungkyunkwan University, 06351 - Seoul/KR
  • 11 Biostatistics, Bristol-Myers Squibb, 1420 - Braine-l'Alleud/BE
  • 12 Hematology/oncology, Pinnacle Research Group, Llc, 36207 - Anniston/US
  • 13 Gastroenterological Surgery, Tokyo National Center for Global Health and Medicine, 162-8655 - Tokyo/JP
  • 14 Gastroenterology, Seoul National University Hospital, 3080 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4663


Despite significant improvements in the treatment of early HCC, curative therapies remain associated with high recurrence rates (≈70% at 5 y) (EASL. J Hepatol 2018), and therefore, adjuvant therapies are needed. Nivolumab (NIVO) has demonstrated durable tumor responses and a manageable safety profile in patients (pts) with advanced HCC, regardless of HCC etiology (CheckMate-040 study) (El-Khoueiry, et al. Lancet 2017). Additionally, NIVO has shown clinical benefit as adjuvant therapy in melanoma (CheckMate-238 study) (Weber, et al. NEJM 2017). This phase 3, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of adjuvant NIVO in pts with HCC who are at high risk of recurrence after curative hepatic resection or ablation, a population for whom no effective therapies are currently available.

Trial design

The trial will include 530 pts aged ≥18 y with a first diagnosis of HCC (any etiology) who are at high risk for HCC recurrence after curative resection or ablation, and who have well-preserved liver function (Child-Pugh score 5 or 6), randomized (1:1) to receive NIVO (480 mg intravenous Q4W) or placebo (PBO). Additional eligibility criteria include Eastern Cooperative Oncology Group performance status of 0 or 1, no evidence of tumor metastasis, no prior therapy for HCC (including loco-regional therapies), and no liver transplant. Pts will be treated until recurrence per blinded independent central review (BICR) assessment, unacceptable toxicity, or withdrawal, or for up to 1 y total duration. Survival follow-up will continue for up to 5 y. The primary endpoint is to compare recurrence-free survival, per BICR assessment. Secondary endpoints include overall survival and time to recurrence (defined as time from randomization to first documented disease recurrence). The trial will be open for enrollment in 20 countries worldwide and is currently recruiting.

Clinical trial identification


Legal entity responsible for the study

Bristol-Meyers Squibb.


Bristol-Meyers Squibb.

Editorial Acknowledgement

Professional medical writing assistance and editorial assistance was provided by Andrea Hammons PhD, and Christine Craig of PPSI (a PAREXEL company), funded by Bristol-Myers Squibb.


M.J. Jimenez Exposito: Employee, stock owner, stock interest: Bristol-Myers Squibb. L.A. Balart: Research grants, advisor: Merck & Co., Inc. A. Heurgue-Berlot: Personal fees: Gilead, Abbvie, MSD, outside the submitted work. V. Poulart: Employee: Bristol-Myers Squibb. J-H. Yoon: Grants: Bayer HealthCare Pharmaceuticals, outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.